News
$Nurix Therapeutics(NRIX.US$ Nurix Therapeutics (NASDAQ:NRIX) said that the FDA has placed a partial clinical hold on a Phase 1 study of its drug NX-2127 in the treatment of B-cell malignancies as the company’s shifts to a different manufacturing process for the product.
Nurix said patients currently enrolled in the trial who are deriving clinical benefit are allowed to continue receiving the current drug product. The screening and enrollment of new patients has been paused.
The company said it is actively working with the FDA to resolve the hold, which does not affect its other drug programs.
Nurix said patients currently enrolled in the trial who are deriving clinical benefit are allowed to continue receiving the current drug product. The screening and enrollment of new patients has been paused.
The company said it is actively working with the FDA to resolve the hold, which does not affect its other drug programs.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
